These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
376 related articles for article (PubMed ID: 22341702)
21. Three-yr safety and efficacy of everolimus and low-dose cyclosporine in de novo pediatric kidney transplant patients. Ferraresso M; Belingheri M; Ginevri F; Murer L; Dello Strologo L; Cardillo M; Parodi A; Ghirardo G; Guzzo I; Innocente A; Ghio L Pediatr Transplant; 2014 Jun; 18(4):350-6. PubMed ID: 24802342 [TBL] [Abstract][Full Text] [Related]
22. Everolimus in different combinations as maintenance immunosuppressive therapy in heart transplant recipients. Schweiger M; Stiegler P; Puntschart A; Sereinigg M; Prenner G; Wasler A; Tscheliessnigg K Exp Clin Transplant; 2012 Jun; 10(3):273-7. PubMed ID: 22631065 [TBL] [Abstract][Full Text] [Related]
23. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients. Schweiger M; Wasler A; Prenner G; Stiegler P; Stadlbauer V; Schwarz M; Tscheliessnigg K Transpl Immunol; 2006 Jun; 16(1):46-51. PubMed ID: 16701176 [TBL] [Abstract][Full Text] [Related]
24. Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation. Fangmann J; Arns W; Marti HP; Hauss J; Ketteler M; Beckurts T; Boesmueller C; Pohanka E; Martin PY; Gerhardt M; Farese S; Neumayer HH; Floege J; Gurr C; Budde K; Nephrol Dial Transplant; 2010 Jan; 25(1):283-92. PubMed ID: 19773417 [TBL] [Abstract][Full Text] [Related]
25. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989 [TBL] [Abstract][Full Text] [Related]
26. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. Abramowicz D; Del Carmen Rial M; Vitko S; del Castillo D; Manas D; Lao M; Gafner N; Wijngaard P; J Am Soc Nephrol; 2005 Jul; 16(7):2234-40. PubMed ID: 15917338 [TBL] [Abstract][Full Text] [Related]
27. 5-year follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: Retrospective single center assessment. Hiramitsu T; Okada M; Futamura K; Yamamoto T; Tsujita M; Goto N; Narumi S; Watarai Y; Takeda A; Iwasaki K; Uchida K; Kobayashi T Int Immunopharmacol; 2016 Oct; 39():192-198. PubMed ID: 27491025 [TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients. Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307 [TBL] [Abstract][Full Text] [Related]
29. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study. Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776 [TBL] [Abstract][Full Text] [Related]
30. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Herrero JI; Quiroga J; Sangro B; Girala M; Gómez-Manero N; Pardo F; Alvárez-Cienfuegos J; Prieto J Liver Transpl Surg; 1999 Sep; 5(5):414-20. PubMed ID: 10477843 [TBL] [Abstract][Full Text] [Related]
31. De novo everolimus-based therapy in renal transplant recipients: effect on proteinuria and renal prognosis. Loriga G; Ciccarese M; Pala PG; Satta RP; Fanelli V; Manca ML; Serra G; Dessole P; Cossu M Transplant Proc; 2010 May; 42(4):1297-302. PubMed ID: 20534285 [TBL] [Abstract][Full Text] [Related]
32. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients. Ross H; Pflugfelder P; Haddad H; Cantarovich M; White M; Ignaszewski A; Howlett J; Vaillancourt M; Dorent R; Burton JR; J Heart Lung Transplant; 2008 Feb; 27(2):197-202. PubMed ID: 18267227 [TBL] [Abstract][Full Text] [Related]
33. Renal function improvement after conversion to proliferation signal inhibitors during long-term follow-up in heart transplant recipients. Kaplinsky E; González-Costello J; Manito N; Roca J; Barbosa MJ; Nebot M; Salazar-Mendiguchia J; Berdejo J; Mañas P; Miralles A; Cequier A Transplant Proc; 2012 Nov; 44(9):2564-6. PubMed ID: 23146455 [TBL] [Abstract][Full Text] [Related]